Loading filters...
Publications per Year (1672 total)
6
·
5
·
15
·
9
1995
13
·
21
·
23
·
19
·
34
2000
37
·
29
·
37
·
30
·
40
2005
48
·
41
·
38
·
50
·
53
2010
56
·
75
·
78
·
80
·
73
2015
65
·
75
·
70
·
79
·
61
2020
80
·
67
·
70
·
64
·
91
2025
40
·
Loaded
Click to load
50 / 1672 papers loaded(scroll for more)
202640 papers
RAI-refractoryAll Stages2026
Precautionary Behaviors and Side Effects after Radioiodine for Thyroid Disease: A Prospective Cohort Study.
Yielder R et al. Thyroid. 2026
AnaplasticAll Stages2026
Preliminary study on ketone body metabolism in anaplastic thyroid cancer.
Wang J et al. Eur Thyroid J. 2026
RAI-refractoryAdvanced/Metastatic2026
TSH Stimulation Methods Are Associated With Comparable Outcomes in Radioiodine-Avid Metastatic Differentiated Thyroid Cancer: Single Center Retrospective Observational Study.
Ledwon A et al. Thyroid. 2026
RAI-refractoryAll Stages2026
Value of TERT Promoter Mutations for Early Outcomes in Papillary Thyroid Cancer.
Kim MJ et al. Endocr Relat Cancer. 2026
RAI-refractoryAll Stages2026
TERT promoter mutations and recurrence patterns in differentiated thyroid carcinoma.
Ryu HJ et al. Endocr Relat Cancer. 2026
RAI-refractoryAdvanced/Metastatic2026
A Systematic Review of Absorbed Doses and Response in Patients Treated with Radioiodine for Differentiated Thyroid Cancer.
Taprogge J et al. Thyroid. 2026
AnaplasticAdvanced/Metastatic2026
Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers.
Talpacci E et al. Eur Thyroid J. 2026
RAI-refractoryAll Stages2026
Pre-Radioiodine Thyrotropin Thresholds During Withdrawal Preparation in Differentiated Thyroid Cancer after Total Thyroidectomy: A Systematic Review and Meta-Analysis.
Rojas T et al. Thyroid. 2026
RET alteredAll Stages2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
Waliany S et al. Clin Cancer Res. 2026
AnaplasticAdvanced/Metastatic2026
Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues.
Hamidi S et al. J Clin Endocrinol Metab. 2026
TKIAdvanced/Metastatic2026
Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR-(P)DTC.
Machlah YM et al. Endocr Relat Cancer. 2026
RAI-refractoryAll Stages2026
Selective Use of Radioiodine Therapy in Differentiated Thyroid Carcinoma: A Population-Based Cohort Study.
Pathak KA et al. Thyroid. 2026
RAI-refractoryAll Stages2026
Assessing the sodium-iodide symporter (NIS) in pediatric differentiated thyroid carcinoma.
Alves-Junior PAG et al. Eur Thyroid J. 2026
RAI-refractoryAdvanced/Metastatic2026
Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study.
Nakatani R et al. J Clin Endocrinol Metab. 2026
RAI-refractoryAdvanced/Metastatic2026
Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment.
Minaldi E et al. J Clin Endocrinol Metab. 2026
AnaplasticAll Stages2026
Nrf2 shapes response to lysosomal inhibition of radiation-induced senescent thyroid cancer cells.
Mazzoleni B et al. Endocr Relat Cancer. 2026
RET alteredAdvanced/Metastatic2026
Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET.
Hadoux J et al. ESMO Open. 2026
RAI-refractoryAll Stages2026
Prognostic Significance of Detectable Antithyroglobulin Antibodies Based on Analytical Sensitivity in Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin after Radioactive Iodine Treatment.
Kim CA et al. Thyroid. 2026
RAI-refractoryAll Stages2026
Thyroglobulin Cutoffs after Total Thyroidectomy Without Radioiodine in Low- to Intermediate-Risk Thyroid Cancer: A Multicenter Cohort Study.
Kim M et al. Thyroid. 2026
RAI-refractoryAdvanced/Metastatic2026
Real-World Efficacy and Safety of Lenvatinib and Sorafenib in Thyroid Cancer: A Retrospective, Propensity-Score-Matched Study.
Kappenstein M et al. Thyroid. 2026
RAI-refractoryAll Stages2026
The Patterns and Risk Factors for Antidepressant Drug Prescription in Thyroid Cancer Patients and Survivors: Analysis Based on the Korean National Health Insurance Service Database.
Kang YE et al. Thyroid. 2026
BRAF V600EAll Stages2026
Pathologic and radiologic response to neoadjuvant therapy in advanced differentiated thyroid cancer.
Kampel L et al. Eur Thyroid J. 2026
Anaplasticearly2026
Long-term Survivors of Anaplastic Thyroid Cancer: A Genomic Predictive Model.
Greenspun BC et al. J Clin Endocrinol Metab. 2026
RAI-refractoryAll Stages2026
Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.
Patrizio A et al. J Clin Endocrinol Metab. 2026
RAI-refractoryAll Stages2026
Are Total Thyroidectomy and Adjuvant Radioactive Iodine Treatment Required in All Patients with N1b Intermediate-High Risk Papillary Thyroid Carcinoma?
Fujiwara T et al. Thyroid. 2026
AnaplasticAll Stages2026
FOSL1 Orchestrates Epigenetic Reprogramming of Anaplastic Thyroid Cancer and Suppresses NK Cell-Mediated Antitumor Immunity.
Huo Y et al. Cancer Res. 2026
RAI-refractoryAdvanced/Metastatic2026
Approach to the patient: Oncocytic thyroid cancer.
Finnegan EA et al. J Clin Endocrinol Metab. 2026
RAI-refractoryAll Stages2026
Prospective Evaluation of Follow-Up De-Escalation to Primary Care in Differentiated Thyroid Cancer with Excellent Response to Therapy.
Fernández Velasco P et al. Thyroid. 2026
RAI-refractoryAll Stages2026
Mid-to Long-term Outcomes After Single Radiofrequency Ablation of Nontoxic and Toxic Thyroid Nodules.
Dobnig H et al. J Clin Endocrinol Metab. 2026
RET alteredAll Stages2026
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.
Roberts TJ et al. Thyroid. 2026
AnaplasticAll Stages2026
Type 2 Deiodinase in Cancer-Associated Fibroblasts is Required to Sustain Growth of Poorly and Undifferentiated Thyroid Cancer.
De Stefano MA et al. Thyroid. 2026
BRAF V600EAdvanced/Metastatic2026
Anlotinib Plus Sintilimab for BRAFV600E Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial.
Gui L et al. Thyroid. 2026
TKIAdvanced/Metastatic2026
Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma.
Hamidi S et al. Thyroid. 2026
AnaplasticAdvanced/Metastatic2026
Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer.
Kiyota N et al. Eur Thyroid J. 2026
RAI-refractoryAdvanced/Metastatic2026
Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.
Chirra M et al. Clin Cancer Res. 2026
RAI-refractoryearly2026
Salivary and lacrimal disorders in patients treated with radioiodine for differentiated thyroid cancer.
Bondet de La Bernardie S et al. Eur Thyroid J. 2026
RAI-refractoryAll Stages2026
A Temporal Analysis of Surgical Management and Outcomes Following ATA Guideline Updates in Papillary Thyroid Carcinoma: A Real-World Cohort Study of 31,861 Patients in South Korea.
Ryu JS et al. Thyroid. 2026
RAI-refractoryAll Stages2026
Defining the ATA-2025 'consider RAIT' zone in older patients with N1b PTC.
Wang Z et al. Endocr Relat Cancer. 2026
AnaplasticAdvanced/Metastatic2026
ALK Inhibition Prolongs Survival in a Mouse Model of ALK-Positive Anaplastic Thyroid Cancer.
Machlah YM et al. Thyroid. 2026
RAI-refractoryAdvanced/Metastatic2026
AL2846, a novel multi-kinase inhibitor, for previously treated radioiodine-refractory differentiated thyroid cancer: Exploratory clinical results from the phase Ib study.
Shi F et al. Clin Cancer Res. 2026
202510 papers
RAI-refractoryAdvanced/Metastatic2025
Efficacy and Safety of Targeted Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer.
Zhang Y et al. J Clin Endocrinol Metab. 2025
RAI-refractoryAdvanced/Metastatic2025
Next-generation sequencing of targetable gene fusions in radioiodine-refractory thyroid cancer: a multicenter study.
Yoo J et al. Endocr Relat Cancer. 2025
RAI-refractoryAll Stages2025
Dynamic risk stratification in patients with follicular thyroid carcinoma treated with lobectomy.
Yamazaki H et al. Eur Thyroid J. 2025
RAI-refractoryAdvanced/Metastatic2025
Clinical Significance of Successful Ablation in Follicular Thyroid Carcinoma.
Yamazaki H et al. J Clin Endocrinol Metab. 2025
TKIAll Stages2025
Analysis of immediate 503 thyroid carcinoma deaths: trend of single institution in 2005-2024.
Yamazaki H et al. Eur Thyroid J. 2025
RAI-refractoryAll Stages2025
Clinical differences and surgery in follicular vs oncocytic thyroid carcinomas.
Xiang J et al. Endocr Relat Cancer. 2025
RAI-refractoryAdvanced/Metastatic2025
Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification.
Stegenga MT et al. J Clin Endocrinol Metab. 2025
RAI-refractoryAll Stages2025
Thyroid Carcinoma in Birt-Hogg-Dubé Syndrome: Case Series and Review of Literature.
Vaid S et al. Thyroid. 2025
RAI-refractoryAdvanced/Metastatic2025
TSHR in thyroid cancer: bridging biological insights to targeted strategies.
Xu S et al. Eur Thyroid J. 2025
RAI-refractoryAll Stages2025
Development and validation of long-acting recombinant human TSH using SAFA technology.
Kim D et al. Endocr Relat Cancer. 2025